低级别小鼠胶质瘤进展为胶质母细胞瘤过程中基因组谱的演变
研究利用基因工程小鼠模型、组织病理学、遗传谱系追踪、表达谱分析和拷贝数分析,探讨低级别胶质瘤恶性进展为高级别肿瘤过程中基因组肿瘤多样性的演变。结果显示,敲除全部3种视网膜母细胞瘤(Rb)家族蛋白是成年小鼠星形胶质细胞启动低级别肿瘤所必需的,KrasG12D突变可增强Rb介导的肿瘤发生;低级别肿瘤显示突变Kras特异性转录组谱但缺乏拷贝数突变,这些肿瘤随机进展为高级别,部分通过获得拷贝数突变实现;高级别肿瘤转录组异质性由3种亚型组成,模拟人间叶型、前神经型和神经型胶质母细胞瘤,并在验证集中得到确认。结论提示致癌驱动突变影响低级别肿瘤基因组谱,这些突变及进展获得性突变共同强烈促成高级别肿瘤的基因组异质性。
要点
- 敲除全部3种Rb家族蛋白是成年小鼠星形胶质细胞启动低级别肿瘤所必需的。
- KrasG12D突变可增强Rb介导的肿瘤发生,低级别肿瘤缺乏拷贝数突变。
- 高级别肿瘤转录组异质性由3种亚型组成,模拟人胶质母细胞瘤亚型。
核心结论
- 结果表明致癌驱动突变影响低级别肿瘤的基因组谱,这些突变及进展获得性突变共同强烈促成高级别肿瘤的基因组异质性。
研究设计与样本
- 研究使用基因工程小鼠模型、组织病理学、遗传谱系追踪、表达谱分析和拷贝数分析,检查低级别向高级别恶性进展过程中基因组肿瘤多样性的演变。
主要发现
- 敲除全部3种视网膜母细胞瘤(Rb)家族蛋白是成年小鼠星形胶质细胞启动低级别肿瘤所必需的。
- 激活丝裂原活化蛋白激酶信号转导的突变,特别是KrasG12D,增强了Rb介导的肿瘤发生。
- 低级别肿瘤显示突变Kras特异性转录组谱,但缺乏拷贝数突变。
- 这些肿瘤随机进展为高级别,部分通过获得拷贝数突变实现。
- 高级别肿瘤转录组异质性由3种亚型组成,模拟人间叶型、前神经型和神经型胶质母细胞瘤,并在不同驱动突变启动的高级别小鼠肿瘤验证集、人患者来源异种移植模型和胶质母细胞瘤肿瘤中得到确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gliomas are diverse neoplasms with multiple molecular subtypes. How tumor-initiating mutations relate to molecular subtypes as these tumors evolve during malignant progression remains unclear. METHODS: We used genetically engineered mouse models, histopathology, genetic lineage tracing, expression profiling, and copy number analyses to examine how genomic tumor diversity evolves during the course of malignant progression from low- to high-grade disease. RESULTS: Knockout of all 3 retinoblastoma (Rb) family proteins was required to initiate low-grade tumors in adult mouse astrocytes. Mutations activating mitogen-activated protein kinase signaling, specifically KrasG12D, potentiated Rb-mediated tumorigenesis. Low-grade tumors showed mutant Kras-specific transcriptome profiles but lacked copy number mutations. These tumors stochastically progressed to high-grade, in part through acquisition of copy number mutations. High-grade tumor transcriptomes were heterogeneous and consisted of 3 subtypes that mimicked human mesenchymal, proneural, and neural glioblastomas. Subtypes were confirmed in validation sets of high-grade mouse tumors initiated by different driver mutations as well as human patient-derived xenograft models and glioblastoma tumors. CONCLUSION: These results suggest that oncogenic driver mutations influence the genomic profiles of low-grade tumors and that these, as well as progression-acquired mutations, contribute strongly to the genomic heterogeneity across high-grade tumors.
引用
- Vitucci M, Irvin DM, McNeill RS, et al. Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma. Neuro Oncol. 2017. PMID: 28398584. doi:10.1093/neuonc/nox050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。